Mrs. Erony joined Signet Healthcare Partners in 2006 and has more than 25 years experience as a principal in investing activities, investment banking and business development. She is currently a Director of IGI Labs and Fluxion and has been a Director of Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Atlantis Components (acquired by AstraZeneca) , and Control Delivery Systems (acquired by Psivida).

Previously, Mrs. Erony was a strategic advisor to Alcon Labs and was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies.

Mr. Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A. and Pfenex Inc., and also serves on the Board of Directors of Spepharm BV, Paladin Laboratories, Octoplus BV, IGI, Inc., and Anteis SA.

Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale’s investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co.

Mr. Gale received his Masters of Business Administration from the University of Chicago.

Mr. Hansen has been a Managing Director of Signet Healthcare Partners since 2001. Mr. Hansen has almost 20 years of private equity investment experience.

He is Chairman of Bioject and Cedarburg Pharmaceuticals. He is also a Director of BioPro Pharmaceutical, LearnWright, Malladi Drugs and Pfenex. He is a former Chairman and interim CEO of Questcor Pharmaceuticals.

Prior to Signet, Mr. Hansen’s was a principal of Darby Overseas, since acquired by Franklin Templeton. He was also Director of Corporate Finance at the U.S. Treasury Department in 1992.

Earlier in his career, Mr. Hansen was an investment banker with Dillon Read & Co. Inc., focusing on mergers and acquisitions. He was also an investment banker at E.F. Hutton & Co. Mr. Hansen also served in the U.S. Army as an Infantry and Special Forces officer.

Mr. Hansen has a B.A. from Princeton University and a Masters of Business Administration (with distinction) from the Wharton School, University of Pennsylvania.

Mr. Sone, Managing Director, of Signet was previously an Investment Director at Joddes Limited, an investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was the Director of Strategic Planning at Pharmascience Inc., one of the largest privately-owned generic pharmaceutical companies in the world. Mr. Sone is a director of Arbor Pharmaceuticals.

Prior to joining Pharmascience, Mr. Sone was a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.

Mr. Sone received a Bachelor of Commerce (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.